

## **2004 Cardiovascular Biomarkers and Surrogate Endpoints Symposium**

In September of 2004, 6 months after the publication of the FDA's **Critical Path Initiative**, the **Cardiovascular Biomarkers and Surrogate Endpoints Symposium**, continued its efforts to educate, inform, and foster collaboration between academia, industry, and regulatory agencies with the establishment of the symposium as an annual event. The scope of this second annual symposium (2004) was expanded to include biomarkers in the setting of diabetes, acute coronary syndrome, and the development of devices (*Appendix C*). Additionally, the symposium became a truly international collaboration with the inclusion of the European perspective on biomarkers in drug development with contributions from the European Agency for the Evaluation of Medicinal Products (EMA). The faculty was reflective of the scope of the program (*Appendix D*).